A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04083976 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 10, 2019
Last Update Posted : April 24, 2024
|
Sponsor:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Janssen Research & Development, LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | December 4, 2023 |
| Estimated Study Completion Date : | September 20, 2024 |